Home Cart Sign in  
Chemical Structure| 34981-26-5 Chemical Structure| 34981-26-5

Structure of Kurarinone
CAS No.: 34981-26-5

Chemical Structure| 34981-26-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Kurarinone is a flavonoid isolated from Sophora flavescens, possessing antitumor, estrogenic, and anti-inflammatory activities, and inhibiting Th1 and Th17 cell differentiation.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Kurarinone

CAS No. :34981-26-5
Formula : C26H30O6
M.W : 438.51
SMILES Code : O=C1C[C@@H](C2=CC=C(O)C=C2O)OC3=C1C(OC)=CC(O)=C3C[C@H](C(C)=C)CC=C(C)C
InChI Key :LTTQKYMNTNISSZ-MWTRTKDXSA-N
Pubchem ID :11982640

Safety of Kurarinone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MSSA ATCC 25923 3.9 µg/mL 18 hours To evaluate the antibacterial activity of Kurarinone against MSSA ATCC 25923, results showed significant antibacterial activity J Adv Res. 2024 Mar;57:197-212
MSSA ATCC 29213 7.8 µg/mL 18 hours To evaluate the antibacterial activity of Kurarinone against MSSA ATCC 29213, results showed significant antibacterial activity J Adv Res. 2024 Mar;57:197-212
MRSA (USA300) 7.8 µg/mL 18 hours To evaluate the antibacterial activity of Kurarinone against MRSA, results showed significant antibacterial activity J Adv Res. 2024 Mar;57:197-212
HaCaT cells 50 μM 6 hours To evaluate the effect of Kurarinone on HO-1 expression, results showed that Kurarinone induced HO-1 expression. Antioxidants (Basel). 2020 Sep 9;9(9):842
RAW264.7 cells 50 μM 6 hours To evaluate the effect of Kurarinone on HO-1 expression, results showed that Kurarinone induced HO-1 expression. Antioxidants (Basel). 2020 Sep 9;9(9):842
PC3 cells 50 μM 6 hours To evaluate the effect of Kurarinone on HO-1 mRNA expression, results showed that Kurarinone significantly increased HO-1 mRNA expression. Antioxidants (Basel). 2020 Sep 9;9(9):842
BEAS-2B cells 5, 10, 15, 20 mg/mL 12, 24, 48 hours To evaluate the toxicity of Kurarinone on BEAS-2B cells. Results showed that Kurarinone had low toxicity on BEAS-2B cells. Front Pharmacol. 2018 Mar 23;9:252
NCI-H1975 cells 5, 10, 15, 20 mg/mL 12, 24, 48 hours To evaluate the inhibitory effect of Kurarinone on the proliferation of NCI-H1975 cells. Results showed that Kurarinone had significant cytotoxicity against NCI-H1975 cells. Front Pharmacol. 2018 Mar 23;9:252
A549 cells 5, 10, 15, 20 mg/mL 12, 24, 48 hours To evaluate the inhibitory effect of Kurarinone on the proliferation of A549 cells. Results showed that Kurarinone inhibited the proliferation of A549 cells in a time- and dose-dependent manner. Front Pharmacol. 2018 Mar 23;9:252
CDLN cells 20 μg/ml 72 hours To investigate the effect of KU on Th17 cell differentiation and Rac1 expression in CDLN cells. Results showed that KU significantly inhibited Th17 cell differentiation and Rac1 expression. J Adv Res. 2025 Mar;69:381-398
Peripheral blood mononuclear cells (PBMCs) 10 and 20 μg/ml 72 hours To evaluate the effect of KU on inflammatory cytokine production in PBMCs. Results showed that KU significantly inhibited Th17 cell differentiation and Rac1 expression, and reduced inflammatory cytokine production. J Adv Res. 2025 Mar;69:381-398
B16F10 cells 5 and 10 μM 48 hours Enhanced intracellular tyrosinase activity and stimulated melanin production Front Pharmacol. 2024 Jul 10;15:1422310

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Zebra fish Zebra fish larvae 20 μM 48 hours Stimulated melanogenesis by 36.9% Front Pharmacol. 2024 Jul 10;15:1422310
C57BL/6J mice Experimental autoimmune uveitis (EAU) model Intraperitoneal injection 10, 20, 40 mg/kg Once daily for 14 days To evaluate the therapeutic effect of KU on EAU model mice. Results showed that KU significantly alleviated EAU symptoms, reduced retinal inflammatory cell infiltration, and regulated Th17/Treg balance. J Adv Res. 2025 Mar;69:381-398
ICR mice MRSA skin wound infection model Topical administration 7.8 mg/kg Once daily for 14 days To evaluate the therapeutic effect of Kurarinone on MRSA skin wound infection, results showed significant promotion of wound healing and reduction of bacterial load J Adv Res. 2024 Mar;57:197-212
BALB/c mice Bleomycin-induced pulmonary fibrosis model Oral 5 mg/kg and 10 mg/kg Five times a week from day 7 to day 27 after bleomycin administration Kurarinone improved mechanical lung function, reduced collagen accumulation in lung tissues, and suppressed phosphorylation of Smad2/3 and AKT in bleomycin-induced pulmonary fibrosis mice. Int J Mol Sci. 2021 Aug 4;22(16):8388
C57BL/6 mice TNBS-induced colitis model Intraperitoneal injection 125 mg/kg/day Once daily for 7 days KAR significantly alleviates TNBS-induced colitis symptoms, including reduced weight loss, lower disease activity index, improved colonic tissue damage, decreased inflammatory cell infiltration, protection of goblet cells and tight junction structures, and restoration of gut microbiota balance. Mechanistically, KAR suppresses Th17 cell response and promotes IL-10 production via Blimp-1 Front Immunol. 2025 May 1;16:1587479
BALB/c nude mice A549 xenograft model Intraperitoneal injection 20 and 40 mg/kg/day Once daily for 27 days To evaluate the inhibitory effect of Kurarinone on the growth of A549 xenograft tumors in vivo. Results showed that Kurarinone significantly inhibited tumor growth without apparent toxicity. Front Pharmacol. 2018 Mar 23;9:252
Mice MPTP-induced PD model 5, 10, and 20 mg/kg Kurarinone dose-dependently alleviated MPTP-induced behavioral deficits and dopaminergic neurotoxicity, including the losses of neurotransmitters and tyrosine hydroxylase (TH)-positive cells. Furthermore, kurarinone attenuated MPTP-mediated neuroinflammation by suppressing the activation of microglia involved in the nuclear factor kappa B signaling pathway. Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):e2118818119
DBA/1 mice Collagen-induced arthritis (CIA) model Oral 100 mg/kg/day Once daily for 21 days Reduced arthritis symptoms, decreased inflammatory cytokine levels, inhibited Th1 and Th17 cell responses, and reduced oxidative stress Int J Mol Sci. 2021 Apr 13;22(8):4002

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.28mL

0.46mL

0.23mL

11.40mL

2.28mL

1.14mL

22.80mL

4.56mL

2.28mL

 

Historical Records

Categories